Developer docs
API playgroundTry for free, no card

Search company profiles

Athena Diagnostics

Full company profile

uuid00071uc

Namestring
Athena Diagnostics
Legal namestring
Athena Diagnostics, Inc.
Company typeenum
Private
Founded yearint
1988
Descriptiontext

Athena Diagnostics, Inc. is a U.S. reference laboratory founded in 1988 and headquartered in Marlborough, Massachusetts, operating as a wholly-owned subsidiary of Quest Diagnostics (NYSE: DGX). The company specializes in genetic and diagnostic testing for neurological, endocrine, and renal conditions, offering a catalog of more than 400 tests that span Alzheimer's disease (ADmark evaluations), epilepsy panels, hereditary ataxia, Charcot-Marie-Tooth disease, hereditary spastic paraplegia, muscular dystrophy, myasthenia gravis autoantibodies, paraneoplastic syndromes (Recombx profiles), monogenic diabetes (MODY), polycystic kidney disease, and related neuromuscular and developmental disorders. Its technology stack combines proprietary genetic assays, reflexive testing algorithms, and a patent portfolio exceeding 100 issued U.S. patents covering core test methodologies. The lab is credentialed under CLIA (22D0069726), CAP (3733701), ISO 14001, and holds individual state clinical laboratory licenses in CA, MA, MD, NY, PA, and RI, alongside a Medicare provider number and Medicaid enrollment in ME, MA, and OH.\n\nAthena sells its services primarily to neurologists, endocrinologists, nephrologists, hospitals, reference labs, and genetic counselors through physician-order requisition forms, with sample collection handled via the Quest Diagnostics Patient Service Center network or via direct-to-patient saliva collection kits. The company monetizes through direct billing to in-network commercial insurers (Aetna, Anthem BCBS, Cigna, Harvard Pilgrim, Empire/Federal/Horizon BCBS variants, etc.), Medicare Part B (for non-molecular tests), Medicaid in enrolled states, and patient self-pay via the Advance Pay Program (20% cash discount on genetic tests). The Athena Alliance Program provides income-based financial assistance (broadened to 400% of federal poverty guidelines effective September 1, 2025). Supporting platforms include IntelliTest Manager (electronic ordering), AthenaInsight (variant re-investigation), eResults, AutoFax, Quanum Lab Services Manager, and pre-authorization concierge support for clinicians and patients.

Short descriptiontext

Athena Diagnostics, a wholly-owned Quest Diagnostics subsidiary, operates a reference laboratory offering 400+ genetic and diagnostic tests for neurological, endocrine, and renal conditions, serving neurologists, endocrinologists, nephrologists, hospitals, and patients across the United States.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMarlborough, United States
HQ citystring
Marlborough
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurological diagnostic testing, genetic testing services, clinical reference laboratory, neurology genetic panels, Alzheimer's diagnostic evaluation
Industry4 codes
PRIMARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAHAAAK
Autoimmune, Allergy & Specialized Immunology Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAKAIAD
Neuromuscular Medicine (ALS, Myasthenia, Neuropathy)
SECONDARYHLAKAHAO
Genetic & Rare Kidney Disease Clinics
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Clinical Reference Laboratory Services
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Diagnostic Laboratory Testing Services
TypeSubscription Recurring
Description

Clinical laboratory testing services for neurological, endocrine, and renal conditions. Revenue generated through direct billing to insurance (in-network and out-of-network) and patient self-pay arrangements.

athenadiagnostics.com
2Commercial Insurance Billing
TypeSubscription Recurring
Description

For in-network patients, services are billed directly to contracted insurance plans with no upfront patient charges. For out-of-network patients, claims are filed and patients may be billed for uncovered charges.

athenadiagnostics.com
3Medicare and Medicaid Billing
TypeSubscription Recurring
Description

Medicare Part B billing for non-molecular tests in Massachusetts. Medicaid enrollment in Maine, Massachusetts, and Ohio. Hospital inpatient/outpatient Medicare claims are billed directly to Medicare.

athenadiagnostics.com
4Self-Pay and Advance Pay
TypeSubscription Recurring
Description

Discounted cash payment option (20% discount) for patients paying out-of-pocket for genetic testing. Financial assistance through Athena Alliance Program for qualifying uninsured or underinsured patients.

athenadiagnostics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details5 tiers
1Financial Assistance - Athena Alliance Program
ModelOtherBilling cadencePay-as-you-go
Notes

Financial assistance program reducing patient invoices based on income eligibility. Starting September 1, 2025, available to patients with incomes up to 400% of federal income guidelines.

athenadiagnostics.com
2Advance Pay - Cash Discount
ModelSubscriptionBilling cadencePay-as-you-go
Notes

20% discount when paying with cash instead of going through insurance for genetic testing only.

athenadiagnostics.com
3Medicare Part B - Non-Molecular Tests
ModelSubscriptionBilling cadencePay-as-you-go
Notes

Patients with Medicare Part B are not responsible for any payment for non-molecular tests. Signed ABN required for molecular tests as Medicare may not cover molecular testing.

athenadiagnostics.com
4Medicare Advantage
ModelSubscriptionBilling cadencePay-as-you-go
Notes

Claims filed with patient's health plan. Patient liable for balance due. If patient responsibility exceeds $100, patient may qualify for financial assistance.

athenadiagnostics.com
5In-Network Commercial Insurance
ModelSubscriptionBilling cadencePay-as-you-go
Notes

Patients subject to deductible, co-insurance, or co-pay obligations of their plan. No upfront charges paid to Athena Diagnostics unless testing is not covered by contracted payer.

athenadiagnostics.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Athena Diagnostics is a clinical reference laboratory providing more than 400 genetic and diagnostic tests for neurological, endocrine, and renal conditions. The company develops and commercializes proprietary panels for Alzheimer's disease (ADmark), muscular dystrophy, epilepsy, ataxia, hereditary spastic paraplegia, Charcot-Marie-Tooth disease, paraneoplastic syndromes, monogenic diabetes (MODY), polycystic kidney disease, and Rett syndrome. Services are ordered by physicians and delivered with results via AutoFax, eResults, Quanum Lab Services Manager, or mailed reports.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Athena Diagnostics is a diagnostic testing laboratory offering a comprehensive menu of over 400 genetic and diagnostic tests for neurological, endocrine, and renal conditions. The company's portfolio centers on genetic testing panels for complex disorders including Alzheimer's disease (ADmark tests), epilepsy, ataxia, hereditary spastic paraplegia, Charcot-Marie-Tooth disease, and paraneoplastic syndromes. Test results are delivered through multiple platforms including AutoFax, eResults, and Quanum Lab Services Manager. Supporting services include AthenaInsight for variant re-investigation, IntelliTest Manager for test ordering, and the Athena Alliance Program for financial assistance. The company operates under CLIA certification and holds multiple state laboratory licenses across the United States.

Product and service18 records
1Diagnostic Testing Services
CategoryReference laboratory diagnostic testing services
Description

Comprehensive genetic and diagnostic testing services for neurological, endocrine, and renal conditions, offering over 400 diagnostic tests including Alzheimer's disease evaluation, epilepsy panels, ataxia assessments, hereditary spastic paraplegia testing, and muscular dystrophy analysis. For physicians, neurologists, endocrinologists, nephrologists, hospitals, and reference laboratories.

2ADmark Alzheimer's Evaluation
CategoryNeurological genetic and biomarker testing
Description

Comprehensive Alzheimer's disease diagnostic evaluation including ADmark Early Onset Alzheimer's Evaluation, ADmark PS-1 and PS-2 DNA sequencing tests, and ADmark Phospho-Tau/Total-Tau/Ab42 CSF analysis for symptomatic patients.

3Epilepsy Advanced Sequencing and CNV Evaluation
CategoryNeurological genetic testing
Description

Advanced genetic testing for epilepsy including sub-panels covering generalized absence, focal, febrile, myoclonic epilepsies, epileptic encephalopathy, developmental brain malformations, intellectual disability, neuronal ceroid lipofuscinosis, epilepsy with migraine, syndromic disorders, and infantile spasms.

4Ataxia Evaluation Suite
CategoryNeurological genetic testing
Description

Comprehensive ataxia evaluation including autosomal dominant, autosomal recessive, common repeat expansion, and supplemental recessive evaluations, plus ataxia-telangiectasia (ATM) DNA deletion and sequencing analysis.

5Hereditary Spastic Paraplegia (HSP) Evaluation
CategoryNeurological genetic testing
Description

Genetic evaluation for hereditary spastic paraplegia including comprehensive, common sporadic, complete dominant, common dominant, and complete recessive evaluations.

6CMT Advanced Evaluation
CategoryNeurological genetic testing
Description

Comprehensive evaluation for Charcot-Marie-Tooth disease including initial genetic assessment and complete comprehensive panels.

7Paraneoplastic Evaluation
CategoryNeurological autoimmune testing
Description

Paraneoplastic syndrome testing including NeoCerebellar Degeneration, NeoComplete, NeoEncephalitis, NeoSeM Basic, and NeoSensory Neuropathy profiles with Recombx autoantibody detection.

8Monogenic Diabetes (MODY) Evaluation
CategoryEndocrine genetic testing
Description

Genetic testing for monogenic diabetes including 5-gene MODY evaluation, HNF4A (MODY1), HNF1A (MODY3), HNF1B (MODY5), CEL (MODY8), and neonatal diabetes mellitus evaluation.

9Complete PKD Evaluation
CategoryRenal genetic testing
Description

Comprehensive evaluation for polycystic kidney disease including familial mutation evaluation and sequencing analysis.

10Complete Rett Syndrome Evaluation
CategoryNeurological genetic testing
Description

Comprehensive MECP2 testing including DNA sequencing and duplication/deletion analysis for Rett syndrome diagnosis.

11Complete SMA Evaluation
CategoryNeuromuscular genetic testing
Description

Spinal muscular atrophy testing including reflexive evaluation, SMA Plus, SMN DNA sequencing, and carrier testing.

12Complete Ataxia Evaluation
CategoryNeurological genetic testing
Description

Comprehensive ataxia genetic testing covering autosomal dominant ataxia (SCA1, SCA3, SCA5, SCA6, SCA7, SCA8, SCA10, SCA13, SCA14), autosomal recessive ataxia, and Friedreich ataxia.

13AthenaInsight Variant Investigation
CategoryVariant investigation and re-analysis service
Description

Variant investigation and re-analysis service allowing clinicians to request re-analysis for previously reported genetic findings. Includes Family Insight Program forms for download.

14Test Results Delivery Platforms
CategoryTest results delivery platforms
Description

Multiple options for receiving test results including AutoFax (low-medium volume private/small group practice), Mailed Reports (all volumes), eResults (all volumes with secure colleague forwarding), and Quanum Lab Services Manager (medium-high volume physician practice and hospital/lab setting).

15IntelliTest Manager
CategoryTest ordering and management platform
Description

Test management tool for ordering and tracking diagnostic tests through the Athena Diagnostics system.

16Saliva Collection Kit
CategorySample collection kit
Description

Home-based saliva collection kit that can be shipped directly to patients for at-home genetic testing sample collection.

17Athena Alliance Program
CategoryFinancial assistance program
Description

Financial assistance program offering reduced patient costs for genetic testing, with eligibility up to 400% of federally established income guidelines as of September 1, 2025.

18Advance Pay Program
CategoryPatient payment program
Description

Cash payment option providing patients with a 20% discount when paying directly rather than through insurance for genetic testing.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeOthers
Description

Athena Diagnostics is a subsidiary of Quest Diagnostics, utilizing the Quest Diagnostics Patient Service Center network for sample collection and maintaining shared infrastructure and laboratory resources.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

ARUP is a nonprofit reference laboratory that provides esoteric and specialty diagnostic testing across neurology, genetics, and metabolic disorders. It directly competes with Athena in neurological genetic testing and serves similar hospital and physician clients with complex specialty panels.

TypeDirect peer
Description

Mayo Clinic Laboratories is a major reference laboratory offering specialty genetic and neurological testing through Mayo Clinic's clinical expertise. It competes directly with Athena in neurology, endocrinology, and rare disease genetic panels, serving similar specialist physician customers.

TypeBroad incumbent
Description

Labcorp is one of the largest U.S. clinical laboratory networks offering extensive genetic and specialty testing. While it operates at a much broader scale than Athena, it directly competes on neurological genetic panels, neuromuscular testing, and Alzheimer's biomarker services.

TypeDirect peer
Description

GeneDx is a specialty clinical genomics company offering whole exome sequencing, rare disease panels, and neurological genetic testing. It competes directly with Athena's neurogenetic testing menu including epilepsy, ataxia, and neuromuscular disorder panels for pediatric and adult neurology customers.

TypeDirect peer
Description

Ambry Genetics (a Konica Minolta company) specializes in clinical genetic testing for hereditary cancer, neurology, and rare diseases. It competes with Athena on neurological and rare disease genetic panels with overlapping reflexive testing algorithms serving similar specialist clinicians.

TypeDirect peer
Description

PreventionGenetics is a clinical DNA testing laboratory offering comprehensive genetic testing across neurology, neuromuscular disorders, and rare diseases. It overlaps with Athena's test menu in areas such as ataxia, epilepsy, CMT, and other neurogenetic conditions.

TypeDirect peer
Description

Blueprint Genetics (now part of Quest Diagnostics) specializes in rare disease genetic testing with a focus on neurological, cardiovascular, and metabolic disorders. As a Quest-owned entity, it is a sibling company to Athena with overlapping test menus in neurological genetics.

TypeBroad incumbent
Description

Quest Diagnostics is Athena's parent company and the largest U.S. clinical laboratory. While Athena is a focused subsidiary, Quest's broader genetic and specialty testing portfolio competes in adjacent areas including BRCA, pharmacogenomics, and general molecular diagnostics.

TypeEmerging player
Description

C2N Diagnostics is an emerging specialty diagnostics company offering blood-based Alzheimer's biomarker testing (PrecivityAD). It represents a potential substitute modality for Athena's CSF-based ADmark Alzheimer's evaluations, particularly as blood-based biomarkers gain traction.

TypeEmerging player
Description

Quanterix provides ultra-sensitive blood-based biomarker testing using Simoa technology, including neurology and neurodegeneration assays. It represents an emerging alternative diagnostic platform that could compete with Athena's neurology biomarker testing over time.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature14 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance11 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Athena Diagnostics

Clinical Reference Laboratory Servicesathenadiagnostics.com

Athena Diagnostics, a wholly-owned Quest Diagnostics subsidiary, operates a reference laboratory offering 400+ genetic and diagnostic tests for neurological, endocrine, and renal conditions, serving neurologists, endocrinologists, nephrologists, hospitals, and patients across the United States.

What Athena Diagnostics does

Athena Diagnostics, Inc. is a U.S. reference laboratory founded in 1988 and headquartered in Marlborough, Massachusetts, operating as a wholly-owned subsidiary of Quest Diagnostics (NYSE: DGX). The company specializes in genetic and diagnostic testing for neurological, endocrine, and renal conditions, offering a catalog of more than 400 tests that span Alzheimer's disease (ADmark evaluations), epilepsy panels, hereditary ataxia, Charcot-Marie-Tooth disease, hereditary spastic paraplegia, muscular dystrophy, myasthenia gravis autoantibodies, paraneoplastic syndromes (Recombx profiles), monogenic diabetes (MODY), polycystic kidney disease, and related neuromuscular and developmental disorders. Its technology stack combines proprietary genetic assays, reflexive testing algorithms, and a patent portfolio exceeding 100 issued U.S. patents covering core test methodologies. The lab is credentialed under CLIA (22D0069726), CAP (3733701), ISO 14001, and holds individual state clinical laboratory licenses in CA, MA, MD, NY, PA, and RI, alongside a Medicare provider number and Medicaid enrollment in ME, MA, and OH.\n\nAthena sells its services primarily to neurologists, endocrinologists, nephrologists, hospitals, reference labs, and genetic counselors through physician-order requisition forms, with sample collection handled via the Quest Diagnostics Patient Service Center network or via direct-to-patient saliva collection kits. The company monetizes through direct billing to in-network commercial insurers (Aetna, Anthem BCBS, Cigna, Harvard Pilgrim, Empire/Federal/Horizon BCBS variants, etc.), Medicare Part B (for non-molecular tests), Medicaid in enrolled states, and patient self-pay via the Advance Pay Program (20% cash discount on genetic tests). The Athena Alliance Program provides income-based financial assistance (broadened to 400% of federal poverty guidelines effective September 1, 2025). Supporting platforms include IntelliTest Manager (electronic ordering), AthenaInsight (variant re-investigation), eResults, AutoFax, Quanum Lab Services Manager, and pre-authorization concierge support for clinicians and patients.

Athena Diagnostics firmographics

Firmographics
Name
Athena Diagnostics
Legal name
Athena Diagnostics, Inc.
Website
https://athenadiagnostics.com
Company type
Private
Founded year
1988
Operating status
Operating
Headcount range
51–100 employees
Short description
Athena Diagnostics, a wholly-owned Quest Diagnostics subsidiary, operates a reference laboratory offering 400+ genetic and diagnostic tests for neurological, endocrine, and renal conditions, serving neurologists, endocrinologists, nephrologists, hospitals, and patients across the United States.
Ownership category
akta.pro rank

Athena Diagnostics industry classification

Industry
Product category
Clinical Reference Laboratory Services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAHAAAK
Autoimmune, Allergy & Specialized Immunology Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAKAIAD
Neuromuscular Medicine (ALS, Myasthenia, Neuropathy)
SECONDARYHLAKAHAO
Genetic & Rare Kidney Disease Clinics

Keywords

  • Neurological diagnostic testing
  • Genetic testing services
  • Clinical reference laboratory
  • Neurology genetic panels
  • Alzheimer's diagnostic evaluation

Where Athena Diagnostics is headquartered

Location

Headquarters

HQ city
Marlborough
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Athena Diagnostics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Diagnostic Laboratory Testing Services: Clinical laboratory testing services for neurological, endocrine, and renal conditions. Revenue generated through direct billing to insurance (in-network and out-of-network) and patient self-pay arrangements.
  2. Commercial Insurance Billing: For in-network patients, services are billed directly to contracted insurance plans with no upfront patient charges. For out-of-network patients, claims are filed and patients may be billed for uncovered charges.
  3. Medicare and Medicaid Billing: Medicare Part B billing for non-molecular tests in Massachusetts. Medicaid enrollment in Maine, Massachusetts, and Ohio. Hospital inpatient/outpatient Medicare claims are billed directly to Medicare.
  4. Self-Pay and Advance Pay: Discounted cash payment option (20% discount) for patients paying out-of-pocket for genetic testing. Financial assistance through Athena Alliance Program for qualifying uninsured or underinsured patients.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goFinancial Assistance - Athena Alliance Program
SubscriptionPay-as-you-goAdvance Pay - Cash Discount
SubscriptionPay-as-you-goMedicare Part B - Non-Molecular Tests
SubscriptionPay-as-you-goMedicare Advantage
SubscriptionPay-as-you-goIn-Network Commercial Insurance

Go-to-market motion3 records

Distribution channels5 records

Marketing channels4 records

Athena Diagnostics product offering

Product offering

Core offering

Athena Diagnostics is a clinical reference laboratory providing more than 400 genetic and diagnostic tests for neurological, endocrine, and renal conditions. The company develops and commercializes proprietary panels for Alzheimer's disease (ADmark), muscular dystrophy, epilepsy, ataxia, hereditary spastic paraplegia, Charcot-Marie-Tooth disease, paraneoplastic syndromes, monogenic diabetes (MODY), polycystic kidney disease, and Rett syndrome. Services are ordered by physicians and delivered with results via AutoFax, eResults, Quanum Lab Services Manager, or mailed reports.

Product overview

Athena Diagnostics is a diagnostic testing laboratory offering a comprehensive menu of over 400 genetic and diagnostic tests for neurological, endocrine, and renal conditions. The company's portfolio centers on genetic testing panels for complex disorders including Alzheimer's disease (ADmark tests), epilepsy, ataxia, hereditary spastic paraplegia, Charcot-Marie-Tooth disease, and paraneoplastic syndromes. Test results are delivered through multiple platforms including AutoFax, eResults, and Quanum Lab Services Manager. Supporting services include AthenaInsight for variant re-investigation, IntelliTest Manager for test ordering, and the Athena Alliance Program for financial assistance. The company operates under CLIA certification and holds multiple state laboratory licenses across the United States.

Differentiator

Problem solved

Functional benefit

Products and services

  • Diagnostic Testing Services Comprehensive genetic and diagnostic testing services for neurological, endocrine, and renal conditions, offering over 400 diagnostic tests including Alzheimer's disease evaluation, epilepsy panels, ataxia assessments, hereditary spastic paraplegia testing, and muscular dystrophy analysis. For physicians, neurologists, endocrinologists, nephrologists, hospitals, and reference laboratories.
  • ADmark Alzheimer's Evaluation Comprehensive Alzheimer's disease diagnostic evaluation including ADmark Early Onset Alzheimer's Evaluation, ADmark PS-1 and PS-2 DNA sequencing tests, and ADmark Phospho-Tau/Total-Tau/Ab42 CSF analysis for symptomatic patients.
  • Epilepsy Advanced Sequencing and CNV Evaluation Advanced genetic testing for epilepsy including sub-panels covering generalized absence, focal, febrile, myoclonic epilepsies, epileptic encephalopathy, developmental brain malformations, intellectual disability, neuronal ceroid lipofuscinosis, epilepsy with migraine, syndromic disorders, and infantile spasms.
  • Ataxia Evaluation Suite Comprehensive ataxia evaluation including autosomal dominant, autosomal recessive, common repeat expansion, and supplemental recessive evaluations, plus ataxia-telangiectasia (ATM) DNA deletion and sequencing analysis.
  • Hereditary Spastic Paraplegia (HSP) Evaluation Genetic evaluation for hereditary spastic paraplegia including comprehensive, common sporadic, complete dominant, common dominant, and complete recessive evaluations.
  • CMT Advanced Evaluation Comprehensive evaluation for Charcot-Marie-Tooth disease including initial genetic assessment and complete comprehensive panels.
  • Paraneoplastic Evaluation Paraneoplastic syndrome testing including NeoCerebellar Degeneration, NeoComplete, NeoEncephalitis, NeoSeM Basic, and NeoSensory Neuropathy profiles with Recombx autoantibody detection.
  • Monogenic Diabetes (MODY) Evaluation Genetic testing for monogenic diabetes including 5-gene MODY evaluation, HNF4A (MODY1), HNF1A (MODY3), HNF1B (MODY5), CEL (MODY8), and neonatal diabetes mellitus evaluation.
  • Complete PKD Evaluation Comprehensive evaluation for polycystic kidney disease including familial mutation evaluation and sequencing analysis.
  • Complete Rett Syndrome Evaluation Comprehensive MECP2 testing including DNA sequencing and duplication/deletion analysis for Rett syndrome diagnosis.
  • Complete SMA Evaluation Spinal muscular atrophy testing including reflexive evaluation, SMA Plus, SMN DNA sequencing, and carrier testing.
  • Complete Ataxia Evaluation Comprehensive ataxia genetic testing covering autosomal dominant ataxia (SCA1, SCA3, SCA5, SCA6, SCA7, SCA8, SCA10, SCA13, SCA14), autosomal recessive ataxia, and Friedreich ataxia.
  • AthenaInsight Variant Investigation Variant investigation and re-analysis service allowing clinicians to request re-analysis for previously reported genetic findings. Includes Family Insight Program forms for download.
  • Test Results Delivery Platforms Multiple options for receiving test results including AutoFax (low-medium volume private/small group practice), Mailed Reports (all volumes), eResults (all volumes with secure colleague forwarding), and Quanum Lab Services Manager (medium-high volume physician practice and hospital/lab setting).
  • IntelliTest Manager Test management tool for ordering and tracking diagnostic tests through the Athena Diagnostics system.
  • Saliva Collection Kit Home-based saliva collection kit that can be shipped directly to patients for at-home genetic testing sample collection.
  • Athena Alliance Program Financial assistance program offering reduced patient costs for genetic testing, with eligibility up to 400% of federally established income guidelines as of September 1, 2025.
  • Advance Pay Program Cash payment option providing patients with a 20% discount when paying directly rather than through insurance for genetic testing.

Companies that use Athena Diagnostics

Customer profile

Named customers10 records

Segments4 records

Ideal customer profiles4 records

Athena Diagnostics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature14 records

Athena Diagnostics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Quest DiagnosticscoreOthersAthena Diagnostics is a subsidiary of Quest Diagnostics, utilizing the Quest Diagnostics Patient Service Center network for sample collection and maintaining shared infrastructure and laboratory resources.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Athena Diagnostics competitors and assessment

Company assessment

Direct peers

  • ARUP Laboratories: ARUP is a nonprofit reference laboratory that provides esoteric and specialty diagnostic testing across neurology, genetics, and metabolic disorders. It directly competes with Athena in neurological genetic testing and serves similar hospital and physician clients with complex specialty panels.
  • Mayo Clinic Laboratories: Mayo Clinic Laboratories is a major reference laboratory offering specialty genetic and neurological testing through Mayo Clinic's clinical expertise. It competes directly with Athena in neurology, endocrinology, and rare disease genetic panels, serving similar specialist physician customers.
  • GeneDx (formerly Sema4): GeneDx is a specialty clinical genomics company offering whole exome sequencing, rare disease panels, and neurological genetic testing. It competes directly with Athena's neurogenetic testing menu including epilepsy, ataxia, and neuromuscular disorder panels for pediatric and adult neurology customers.
  • Ambry Genetics: Ambry Genetics (a Konica Minolta company) specializes in clinical genetic testing for hereditary cancer, neurology, and rare diseases. It competes with Athena on neurological and rare disease genetic panels with overlapping reflexive testing algorithms serving similar specialist clinicians.
  • PreventionGenetics: PreventionGenetics is a clinical DNA testing laboratory offering comprehensive genetic testing across neurology, neuromuscular disorders, and rare diseases. It overlaps with Athena's test menu in areas such as ataxia, epilepsy, CMT, and other neurogenetic conditions.
  • Blueprint Genetics: Blueprint Genetics (now part of Quest Diagnostics) specializes in rare disease genetic testing with a focus on neurological, cardiovascular, and metabolic disorders. As a Quest-owned entity, it is a sibling company to Athena with overlapping test menus in neurological genetics.

Broad incumbents

  • Labcorp Genetics: Labcorp is one of the largest U.S. clinical laboratory networks offering extensive genetic and specialty testing. While it operates at a much broader scale than Athena, it directly competes on neurological genetic panels, neuromuscular testing, and Alzheimer's biomarker services.
  • Quest Diagnostics: Quest Diagnostics is Athena's parent company and the largest U.S. clinical laboratory. While Athena is a focused subsidiary, Quest's broader genetic and specialty testing portfolio competes in adjacent areas including BRCA, pharmacogenomics, and general molecular diagnostics.

Emerging players

  • C2N Diagnostics: C2N Diagnostics is an emerging specialty diagnostics company offering blood-based Alzheimer's biomarker testing (PrecivityAD). It represents a potential substitute modality for Athena's CSF-based ADmark Alzheimer's evaluations, particularly as blood-based biomarkers gain traction.
  • Quanterix: Quanterix provides ultra-sensitive blood-based biomarker testing using Simoa technology, including neurology and neurodegeneration assays. It represents an emerging alternative diagnostic platform that could compete with Athena's neurology biomarker testing over time.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Athena Diagnostics social profiles

Digital presence

Athena Diagnostics compliance and trust

Trust signal

Compliance11 records

Athena Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Athena Diagnostics leadership team

Management profile

Number of profiles

Profiles12 records

Athena Diagnostics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Athena Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Athena Diagnostics

What does Athena Diagnostics do?

Athena Diagnostics is a clinical reference laboratory providing more than 400 genetic and diagnostic tests for neurological, endocrine, and renal conditions. The company develops and commercializes proprietary panels for Alzheimer's disease (ADmark), muscular dystrophy, epilepsy, ataxia, hereditary spastic paraplegia, Charcot-Marie-Tooth disease, paraneoplastic syndromes, monogenic diabetes (MODY), polycystic kidney disease, and Rett syndrome. Services are ordered by physicians and delivered with results via AutoFax, eResults, Quanum Lab Services Manager, or mailed reports.

Is Athena Diagnostics a public or private company?

Athena Diagnostics is a private company. It is classified as corporate owned and is currently operating.

When was Athena Diagnostics founded?

Athena Diagnostics was founded in 1988. It employs 51 to 100 people.

Where is Athena Diagnostics based?

Athena Diagnostics is headquartered in Marlborough, United States, in the North America region.

How does Athena Diagnostics make money?

Four revenue lines are on record. Diagnostic Laboratory Testing Services are the primary driver. The others are commercial Insurance Billing, medicare and Medicaid Billing and self-Pay and Advance Pay.

Who are Athena Diagnostics's main competitors?

Direct peers on record are ARUP Laboratories, Mayo Clinic Laboratories, GeneDx (formerly Sema4), Ambry Genetics, PreventionGenetics and Blueprint Genetics. Broad incumbents are Labcorp Genetics and Quest Diagnostics. Emerging players are C2N Diagnostics and Quanterix.

Does Athena Diagnostics have an API?

No public API is recorded for Athena Diagnostics.

What industry is Athena Diagnostics in?

Athena Diagnostics's product category is Clinical Reference Laboratory Services. Its primary akta.pro industry code is HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry), with a secondary code of HLAHAAAK, Autoimmune, Allergy & Specialized Immunology Diagnostics. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AthenadiagnosticsAthena DiagnosticsAthena Diagnostics is enrolling in Medicaid programs across the US to improve patient access to genetic testing and is updating its financial assistance program, the Athena Alliance Program. Starting September 1, 2025, this program will be restricted to patients with incomes up to 400% of federal guidelines. The company also highlights new options for commercial insurance and cash-pay discounts.PR NewswireAthena Diagnostics Improves Ataxia Movement Disorder Testing with Novel Long-Read Gene SequencingAthena Diagnostics, a Quest Diagnostics business, announced a new laboratory test for ataxia using PacBio's PureTarget sequencing to detect long repeating DNA sequences. The test confirms PCR screening results and may help guide care decisions, with a preprint study linking a specific pattern to Spinocerebellar ataxia type 10.PR NewswireNew Diagnostic Pathways Could Improve Dementia Diagnosis, According to Consensus Statements to Be Presented at the American Academy of Neurology Annual MeetingQuest Diagnostics and its Athena Diagnostics business, in collaboration with the University of California, San Francisco (UCSF), presented consensus statements at the American Academy of Neurology Annual Meeting advocating for a tiered diagnostic approach to improve dementia screening. These guidelines aim to help primary care physicians efficiently evaluate patients using clinical, imaging, and laboratory data to address the growing prevalence of neurodegenerative disorders.News-MedicalGenetic testing services for rare neurological disorders launched by Athena DiagnosticsAthena Diagnostics, a Quest Diagnostics business, announced clinical availability of new genetic tests for rare neurological disorders, including hereditary neuropathy, neuromuscular disease, epilepsy, and movement disorders. The tests use gene sequencing and bioinformatics with a single blood draw, and include expanded testing for Charcot-Marie-Tooth disease and myofibrillar myopathy.NatureSpinocerebellar ataxia: Patient and health professional perspectives on whether and how patents affect access to clinical genetic testingPatients and health professionals interviewed about patent effects on spinocerebellar ataxia genetic testing found patents reduced access by raising costs, with price and insurance coverage as main barriers. Athena Diagnostics holds exclusive patents on six SCA variants and enforces them, limiting testing to its panel. Cost can reach $7,300, and only 6 of 14 surveyed patients received insurance reimbursement.